As would be expected, high EVPL expression implied a suboptimal response to nivolumab and pembrolizumab in melanoma (Figure 5E), while gastric cancer patients with high ENTPD3 expression responded visibly better to pembrolizumab (Figure 5F). Here, ENTPD3 is linked to gastric cancer.